2/16/2011

Sanofi-Aventis has said it will purchase Genzyme in a cash deal worth $20.1 billion, or $74 per share, plus a contingent-value right related to Genzyme's multiple sclerosis drug Lemtrada. The acquisition represents the second-largest for a biotech firm and is expected to bolster Sanofi's revenues.

Full Story:
Reuters

Related Summaries